December 2020, Drugs Monitor

(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients

December 28, 2020

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease https://doi.org/10.1097/MD.0000000000023720 Thirty-four confirmed COVID-19 patients completed the study. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received… Continue reading "(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients"

(22 Dec 2020) Hydroxychloroquine- early stage use decreased the improvement time

December 28, 2020

Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China https://doi.org/10.5582/bst.2020.03340 A total of 616 patients, including 50 (8.11%) severe and 18 (2.92%) critical patients, were enrolled in our retrospective cohort study. The early use… Continue reading "(22 Dec 2020) Hydroxychloroquine- early stage use decreased the improvement time"

(22 Dec 2020) Methylprednisolone- did not improve prognosis in severe and critical COVID-19 patients

December 28, 2020

Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases https://doi.org/10.12998/wjcc.v8.i23.5952 A total of 102 severe and critically ill COVID-19 patients were included in this study. They were divided into treatment (69, 67.6%) and control groups (33, 32.4%)… Continue reading "(22 Dec 2020) Methylprednisolone- did not improve prognosis in severe and critical COVID-19 patients"

(20 Dec 2020) Methylprednisolone- early use in ICU patients not recommended

December 28, 2020

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study https://doi.org/10.1186/s13054-020-03429-w Out of the 294 critically ill patients affected by COVID-19, 183 (62.2%) received corticosteroids, with methylprednisolone as the most frequently administered corticosteroid (175 accounting for 96%). Of… Continue reading "(20 Dec 2020) Methylprednisolone- early use in ICU patients not recommended"

(19 Dec 2020) Sofosbuvir/daclatasvir-did not significantly alleviate symptoms after 7 days of treatment compared with control

December 22, 2020

Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial https://doi.org/10.1093/jac/dkaa501 IRCT20200403046926N1- Between 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir/daclatasvir treatment arm (n = 27) or… Continue reading "(19 Dec 2020) Sofosbuvir/daclatasvir-did not significantly alleviate symptoms after 7 days of treatment compared with control"

(18 Dec 2020) Tocilizumab- reduced the likelihood of mechanical ventilation or death, but it did not improve survival

December 22, 2020

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia https://doi.org/10.1056/NEJMoa2030340 A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9%… Continue reading "(18 Dec 2020) Tocilizumab- reduced the likelihood of mechanical ventilation or death, but it did not improve survival"

(16 Dec 2020) Umifenovir- significant improvement in Clinical outcomes compared to KALETRA

December 17, 2020

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial https://doi.org/10.1186/s12879-020-05698-w TRIAL REGISTRATION: IRCT20180725040596N2 , The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across… Continue reading "(16 Dec 2020) Umifenovir- significant improvement in Clinical outcomes compared to KALETRA"

(15 Dec 2020) Camostat mesylate-associated with the significant decrease in CRP levels

December 17, 2020

Foistar®(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra®(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients https://www.medrxiv.org/content/10.1101/2020.12.10.20240689v1 A total of 29 patients (7 Foistar group and 22 Kaletra group) was included. The median age was 69,… Continue reading "(15 Dec 2020) Camostat mesylate-associated with the significant decrease in CRP levels"

(14 Dec 2020) Molnupiravir- 93.3% of adverse events were mild

December 17, 2020

Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2 https://www.medrxiv.org/content/10.1101/2020.12.10.20235747v1 Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1 (NCT04392219), randomized, double-blind, placebo-controlled study in healthy volunteers, which… Continue reading "(14 Dec 2020) Molnupiravir- 93.3% of adverse events were mild"

(12 Dec 2020) Itolizumab- reduced IL‐6 level and patients showed pulmonary improvement

December 14, 2020

Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab https://doi.org/10.1002/cti2.1218 Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2/FiO2… Continue reading "(12 Dec 2020) Itolizumab- reduced IL‐6 level and patients showed pulmonary improvement"

Month: December 2020